BR9915986A - Estabilização de macrolìdios - Google Patents

Estabilização de macrolìdios

Info

Publication number
BR9915986A
BR9915986A BR9915986-4A BR9915986A BR9915986A BR 9915986 A BR9915986 A BR 9915986A BR 9915986 A BR9915986 A BR 9915986A BR 9915986 A BR9915986 A BR 9915986A
Authority
BR
Brazil
Prior art keywords
stabilization
macro
macrolydes
crystalline form
relates
Prior art date
Application number
BR9915986-4A
Other languages
English (en)
Inventor
Francois Navarro
Samuel Petit
Guy Stone
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26314797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9915986(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR9915986A publication Critical patent/BR9915986A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Patente de Invenção: <B>"ESTABILIZAçãO DE MACROLìDIOS"<D>. A invenção refere-se à estabilização de macrolídios de polieno e a um particular macrolídio obtido na forma cristalina.
BR9915986-4A 1998-12-07 1999-12-06 Estabilização de macrolìdios BR9915986A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9826882.4A GB9826882D0 (en) 1998-12-07 1998-12-07 Organic compounds
GBGB9904934.8A GB9904934D0 (en) 1998-12-07 1999-03-04 Organic compounds
PCT/EP1999/009521 WO2000033878A2 (en) 1998-12-07 1999-12-06 Stabilization of macrolides

Publications (1)

Publication Number Publication Date
BR9915986A true BR9915986A (pt) 2001-09-04

Family

ID=26314797

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9915986-4A BR9915986A (pt) 1998-12-07 1999-12-06 Estabilização de macrolìdios

Country Status (38)

Country Link
US (5) US6605613B2 (pt)
EP (4) EP2269651A3 (pt)
JP (3) JP3805625B2 (pt)
KR (2) KR100695834B1 (pt)
CN (2) CN1876657B (pt)
AR (3) AR026102A1 (pt)
AT (1) ATE365051T1 (pt)
AU (1) AU759219B2 (pt)
BE (1) BE1012869A3 (pt)
BR (1) BR9915986A (pt)
CA (3) CA2351580C (pt)
CO (1) CO4980847A1 (pt)
CY (1) CY1106870T1 (pt)
CZ (2) CZ302210B6 (pt)
DE (1) DE69936352T3 (pt)
DK (1) DK1137439T4 (pt)
ES (1) ES2288033T5 (pt)
FR (1) FR2786771B1 (pt)
GB (2) GB9826882D0 (pt)
HK (1) HK1038889B (pt)
HU (2) HU230174B1 (pt)
ID (1) ID29250A (pt)
IL (1) IL143092A0 (pt)
IT (1) IT1319701B1 (pt)
MY (2) MY127579A (pt)
NO (2) NO332698B1 (pt)
NZ (2) NZ511936A (pt)
PE (1) PE20001333A1 (pt)
PL (2) PL196627B1 (pt)
PT (1) PT1137439E (pt)
RU (1) RU2243769C2 (pt)
SG (1) SG151072A1 (pt)
SI (1) SI1137439T2 (pt)
SK (2) SK286688B6 (pt)
TR (2) TR200101416T2 (pt)
TW (2) TWI248938B (pt)
WO (1) WO2000033878A2 (pt)
ZA (1) ZA200104360B (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
MXPA04007847A (es) 2002-02-13 2005-02-24 Biogal Gyogyszergyar Metodo para extraer un macrolido de biomateria.
US7452692B2 (en) 2002-02-13 2008-11-18 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Method for extracting a macrolide from biomatter
AR040693A1 (es) * 2002-07-30 2005-04-13 Wyeth Corp Formulaciones parenterales
WO2004089958A2 (en) * 2003-03-31 2004-10-21 TEVA Gyógyszergyár Részvénytársaság Crystallization and purification of macrolides
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
PL1558622T3 (pl) 2003-07-24 2008-06-30 Teva Gyogyszergyar Zartkoerueen Muekoedoe Reszvenytarsasag Sposób oczyszczania makrolidów
KR20060085246A (ko) 2003-09-18 2006-07-26 마커사이트, 인코포레이티드 경공막 전달
US9114198B2 (en) * 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
KR20060126701A (ko) * 2003-12-10 2006-12-08 애크럭스 디디에스 피티와이 리미티드 경피 또는 국소 약물 전달에 따른 원치않는 효과의치료방법
US8551512B2 (en) * 2004-03-22 2013-10-08 Advanced Cardiovascular Systems, Inc. Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
MX2007003731A (es) * 2004-09-29 2007-08-14 Johnson & Johnson Formas de dosis farmaceuticas de compuestos similares a rapamicina amorfos estables.
DK1848431T3 (en) 2005-02-09 2016-04-18 Santen Pharmaceutical Co Ltd LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS
WO2007067566A2 (en) * 2005-12-07 2007-06-14 Wyeth Methods for preparing crystalline rapamycin and for measuring crystallinity of rapamycin compounds using differential scanning calorimetry
US7700614B2 (en) * 2005-12-14 2010-04-20 Abbott Laboratories One pot synthesis of tetrazole derivatives of rapamycin
US20070142422A1 (en) * 2005-12-20 2007-06-21 Wyeth Control of CCI-779 dosage form stability through control of drug substance impurities
KR20140093764A (ko) * 2006-02-09 2014-07-28 산텐 세이야꾸 가부시키가이샤 안정한 제제와 그 제조 및 사용 방법
ES2563288T3 (es) 2006-03-23 2016-03-14 Santen Pharmaceutical Co., Ltd Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular
JP2013527223A (ja) 2010-06-02 2013-06-27 フレゼニウス・カビ・オンコロジー・リミテッド ラパマイシンエステルの安定な医薬組成物
CN103025753A (zh) * 2010-06-07 2013-04-03 泰立克公司 晶体盐酸依泽替米贝非溶剂化物
WO2012017449A1 (en) * 2010-08-04 2012-02-09 Meril Life Sciences Pvt. Ltd Process for preparation of novel 42-0-(heteroalkoxyalkyl) rapamycin compounds with anti-proliferative properties"
ES2753529T3 (es) 2010-11-19 2020-04-13 Biocon Ltd Procesos para la preparación de everolimús y productos intermedios del mismo
JP2014516075A (ja) 2011-06-06 2014-07-07 シェブロン フィリップス ケミカル カンパニー エルピー 癌治療のためのメタロセン化合物の使用
WO2013022201A1 (en) * 2011-08-11 2013-02-14 Dong-A Pharm. Co., Ltd. Process of preparing a stabilized and solubilized formulation of sirolimus derivatives
US9610385B2 (en) 2013-03-07 2017-04-04 Abbott Cardiovascular Systems Inc. Method of fabricating an implantable medical device comprising a rapamycin derivative
IN2013MU02532A (pt) 2013-07-31 2015-06-26 Sahajanand Medical Technologies Pvt Ltd
CN104721158B (zh) * 2013-12-24 2018-01-30 正大天晴药业集团股份有限公司 一种稳定的依维莫司片剂
CN104892632B (zh) * 2015-06-03 2017-12-26 道中道（菏泽）制药有限公司 一种晶体形式的依维莫司及其制备方法
EP3329916A4 (en) 2015-07-28 2019-03-20 Nippon Kayaku Kabushiki Kaisha PHARMACEUTICAL COMPOSITION COMPRISING RAPAMYCIN OR A DERIVATIVE THEREOF, AND PROCESS FOR PRODUCING THE SAME
JP6793651B2 (ja) * 2015-08-28 2020-12-02 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
US20190038605A1 (en) * 2015-09-18 2019-02-07 Nippon Kayaku Kabushiki Kaisha Pharmaceutical composition comprising rapamycin or derivative thereof
WO2017129772A1 (en) 2016-01-29 2017-08-03 Xellia Phamaceuticals Aps Stable pharmaceutical compositions of temsirolimus
WO2017204215A1 (ja) 2016-05-27 2017-11-30 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
KR102051806B1 (ko) * 2018-01-12 2019-12-04 주식회사 종근당 에베로리무스를 포함하는 안정화된 약제학적 제제
EP4126882A1 (en) * 2020-03-27 2023-02-08 Boston Scientific Scimed Inc. Methods for crystallization of drugs
JP2023028473A (ja) * 2021-08-19 2023-03-03 日本マイクロバイオファーマ株式会社 エベロリムスの製造方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3996355A (en) 1975-01-02 1976-12-07 American Home Products Corporation Permanent suspension pharmaceutical dosage form
US4049128A (en) 1976-11-18 1977-09-20 Westinghouse Air Brake Company Control system for automatic railway car coupler
AU543727B2 (en) * 1980-06-02 1985-05-02 Ayerst Mckenna & Harrison Inc. Injectable composition of rapamycin
GB8803836D0 (en) 1988-02-18 1988-03-16 Glaxo Group Ltd Compositions
JPH01249651A (ja) † 1988-02-18 1989-10-04 E I Du Pont De Nemours & Co セラミツク／蒸留可能な結合剤組成物
KR0159766B1 (ko) * 1989-10-16 1998-12-01 후지사와 토모키치로 양모제 조성물
JPH04230389A (ja) * 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体
FI97472C (fi) * 1991-05-07 1996-12-27 American Home Prod Menetelmä terapeuttisesti käyttökelpoisten rapamysiinijohdannaisten valmistamiseksi anti-inflammatorisina ja antifungaalisina aineina
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
SG47580A1 (en) 1992-10-13 1998-04-17 American Home Prod Carbamates of rapamycin
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
RU2181054C2 (ru) * 1994-11-02 2002-04-10 Новартис Аг Микроэмульсионный предконцентрат
US5985890A (en) 1995-06-09 1999-11-16 Novartis Ag Rapamycin derivatives
FR2736550B1 (fr) * 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
PT956034E (pt) * 1996-07-30 2002-12-31 Novartis Ag Composicoes farmaceuticas para o tratamento da rejeicao de transplantes estados inflamatorios ou auto-imunes compreendendo ciclosporina a e 40-o-(2-hidroxietil)-rapamicina
US6362264B1 (en) * 1996-12-20 2002-03-26 Ck Witco Corporation Stabilizer for food contact and medical grade PVC
CA2279259A1 (en) 1997-02-04 1998-08-06 Abbott Laboratories Pain reducing parenteral liposome formulation

Also Published As

Publication number Publication date
SK7662001A3 (en) 2001-12-03
KR100695834B1 (ko) 2007-03-19
GB9826882D0 (en) 1999-01-27
PL348333A1 (en) 2002-05-20
EP1137439A2 (en) 2001-10-04
US20080161334A1 (en) 2008-07-03
NZ511936A (en) 2003-10-31
BE1012869A3 (fr) 2001-04-03
SK287325B6 (sk) 2010-07-07
ES2288033T3 (es) 2007-12-16
PT1137439E (pt) 2007-09-25
CA2732620A1 (en) 2000-06-15
MY127579A (en) 2006-12-29
ITMI992520A1 (it) 2001-06-02
ZA200104360B (en) 2002-01-16
DE69936352T3 (de) 2012-05-03
CY1106870T1 (el) 2012-09-26
US7297703B2 (en) 2007-11-20
US7572804B2 (en) 2009-08-11
HK1038889B (en) 2008-01-25
MY120594A (en) 2005-11-30
RU2243769C2 (ru) 2005-01-10
JP2005200429A (ja) 2005-07-28
US20090270441A1 (en) 2009-10-29
SI1137439T2 (sl) 2012-05-31
SK286688B6 (sk) 2009-03-05
NO20012424D0 (no) 2001-05-16
US7741338B2 (en) 2010-06-22
CA2732620C (en) 2013-08-06
EP2279751A3 (en) 2011-02-16
HUP0104489A3 (en) 2004-05-28
IL143092A0 (en) 2002-04-21
EP1137439B2 (en) 2011-11-23
FR2786771B1 (fr) 2002-12-27
JP5043308B2 (ja) 2012-10-10
SI1137439T1 (sl) 2008-06-30
KR20060096477A (ko) 2006-09-11
CA2351580C (en) 2012-03-20
EP1743657A3 (en) 2007-03-28
JP3805625B2 (ja) 2006-08-02
CA2651609A1 (en) 2000-06-15
NO20012424L (no) 2001-05-16
ID29250A (id) 2001-08-16
CN1261163C (zh) 2006-06-28
CN1876657B (zh) 2013-01-09
AR048073A2 (es) 2006-03-29
TR200101416T2 (tr) 2002-01-21
EP1137439B1 (en) 2007-06-20
US6605613B2 (en) 2003-08-12
CA2351580A1 (en) 2000-06-15
TR200201428T2 (tr) 2002-12-23
AU1657300A (en) 2000-06-26
CN1876657A (zh) 2006-12-13
US20050107418A1 (en) 2005-05-19
DK1137439T4 (da) 2012-03-19
JP2006111637A (ja) 2006-04-27
JP5165199B2 (ja) 2013-03-21
JP2002531527A (ja) 2002-09-24
WO2000033878A2 (en) 2000-06-15
HU228939B1 (en) 2013-07-29
ITMI992520A0 (it) 1999-12-02
HUP0104489A2 (hu) 2002-03-28
DE69936352D1 (de) 2007-08-02
PL196627B1 (pl) 2008-01-31
US6852729B2 (en) 2005-02-08
GB9904934D0 (en) 1999-04-28
DK1137439T3 (da) 2007-09-10
CZ303006B6 (cs) 2012-02-22
SG151072A1 (en) 2009-06-29
EP1743657A2 (en) 2007-01-17
EP2269651A3 (en) 2011-03-09
FR2786771A1 (fr) 2000-06-09
AR026102A1 (es) 2003-01-29
CZ302210B6 (cs) 2010-12-22
CN1374872A (zh) 2002-10-16
KR20010101128A (ko) 2001-11-14
NO334612B1 (no) 2014-04-22
IT1319701B1 (it) 2003-10-27
US20030191148A1 (en) 2003-10-09
NZ527781A (en) 2004-11-26
TW200540179A (en) 2005-12-16
PE20001333A1 (es) 2000-12-12
ES2288033T5 (es) 2012-04-10
NO332698B1 (no) 2012-12-10
HU230174B1 (hu) 2015-09-28
US20020032213A1 (en) 2002-03-14
TWI270550B (en) 2007-01-11
EP2269651A2 (en) 2011-01-05
EP2279751A2 (en) 2011-02-02
TWI248938B (en) 2006-02-11
CZ20012001A3 (cs) 2001-09-12
ATE365051T1 (de) 2007-07-15
WO2000033878A3 (en) 2000-11-02
DE69936352T2 (de) 2008-02-14
PL208854B1 (pl) 2011-06-30
HK1038889A1 (en) 2002-04-04
AU759219B2 (en) 2003-04-10
NO20121113L (no) 2001-05-16
CO4980847A1 (es) 2000-11-27
AR054444A2 (es) 2007-06-27

Similar Documents

Publication Publication Date Title
BR9915986A (pt) Estabilização de macrolìdios
DK1094822T3 (da) Med vand blandbar azalidoplösning
MA27023A1 (fr) Formes cristallines d&#39;azithromycine
ATE243703T1 (de) Antibiotische azalid-zusammensetzungen
ATE227937T1 (de) Geformte eingefrorene konfektstange
DE69840822D1 (de) Operationsmikroskop
IS5528A (is) Ný makrólíð
DE69926740D1 (de) Endoskop
PT1349846E (pt) Amidas de acidos furano-e tiofeno-carboxilicos arilados com efeito bloqueador do canal de potassio
DE69838651D1 (de) Erythromycinderivate
NO20010046D0 (no) Dolastatin-15-derivater
NO20006520D0 (no) Adenosinderivater
PT1100326E (pt) Microcapsulas de libertacao activada por bases
FI981104L (fi) Ksylitolin kiteytys, kiteinen ksylitolituote ja sen käyttö
DK1131331T3 (da) 13-leddede azalider og deres anvendelse som antibiotiske midler
ATE241638T1 (de) 15-gliedrige ketolid-lactame mit antibakterieller wirkung
HUP0303255A3 (en) Salts of avermectins substituted in the 4&#34;-position and having pesticidal properties
DE69942875D1 (de) Angriffs
DE69930277D1 (de) Haarformungszusammensetzung
BR9406332A (pt) Mono-hidrato cristalino de espirostanil-glicosidal
ID29508A (id) Gelagar kancing tarik tenunan
SG83724A1 (en) Novel polyene macrolide compounds and uses
DE69913027D1 (de) Verdampfer
DE59907735D1 (de) Wachstumsregulierende wässrige zusammensetzungen
FI980600L (fi) Laktitolin kiteytys, kiteinen laktitolituote ja sen käyttö

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O E 13 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B15W Others matters related to applications: legal action concerning application

Free format text: INPI-52400.172351/16 ORIGEM: JUIZO DA 031A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO 0119732-44.2016.4.02.5101 ACAO ORDINARIA DE NULIDADE DA DECISAO ADMINISTRATIVA DE INDEFERIMENTO DO PEDIDO AUTOR: NOVARTIS AG REU: AGENCIA NACIONAL DE VIGILANCIA SANITARIA - ANVISA E INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI